Da32 Life Science Tech Acquisition Corp. DALS
We take great care to ensure that the data presented and summarized in this overview for DA32 Life Science Tech Acquisition Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DALS
Top Purchases
Top Sells
About DALS
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors. DA32 Life Science Tech Acquisition Corp. was incorporated in 2021 and is based in New York, New York.
Insider Transactions at DALS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jul 28
2023
|
Arch Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,600,000
-100.0%
|
-
|
|
Jul 28
2023
|
Keith Crandell Director |
SELL
Other acquisition or disposition
|
Indirect |
1,600,000
-100.0%
|
-
|
|
Jul 28
2023
|
Deerfield Management Company, L.P. (Series C) Director |
SELL
Other acquisition or disposition
|
Indirect |
1,600,000
-100.0%
|
-
|
|
Jul 30
2021
|
Da32 Sponsor LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
650,000
+50.0%
|
$6,500,000
$10.0 P/Share
|
|
Jul 30
2021
|
Arch Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
650,000
+22.41%
|
$6,500,000
$10.0 P/Share
|
|
Jul 30
2021
|
Arch Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,600,000
+50.0%
|
$16,000,000
$10.0 P/Share
|
|
Jul 30
2021
|
Keith Crandell Director |
BUY
Grant, award, or other acquisition
|
Indirect |
650,000
+22.41%
|
$6,500,000
$10.0 P/Share
|
|
Jul 30
2021
|
Keith Crandell Director |
BUY
Open market or private purchase
|
Indirect |
1,600,000
+50.0%
|
$16,000,000
$10.0 P/Share
|
|
Jul 30
2021
|
Section 32 Fund 3, LP Director |
BUY
Grant, award, or other acquisition
|
Indirect |
650,000
+30.95%
|
$6,500,000
$10.0 P/Share
|
|
Jul 30
2021
|
Section 32 Fund 3, LP Director |
BUY
Open market or private purchase
|
Direct |
800,000
+50.0%
|
$8,000,000
$10.0 P/Share
|
|
Jul 30
2021
|
Deerfield Management Company, L.P. (Series C) Director |
BUY
Grant, award, or other acquisition
|
Indirect |
650,000
+22.41%
|
$6,500,000
$10.0 P/Share
|
|
Jul 30
2021
|
Deerfield Management Company, L.P. (Series C) Director |
BUY
Open market or private purchase
|
Indirect |
1,600,000
+50.0%
|
$16,000,000
$10.0 P/Share
|